A gynecological preparation from Richter has received marketing authorization in Japan
The partner of Richter Gedeon Nyrt., Fuji Pharma Co., Ltd., received the marketing authorization for the Alyssa combination tablet developed in Japan. The approval means a milestone payment of 10 million euros for Richter’s 100 percent subsidiary, Estetra SRL, Richter announced on Tuesday on the website of the Budapest Stock Exchange.
The Alyssa combined tablet is a preparation for the treatment of dysmenorrhea – painful, crampy menstruation – which contains, among other things, a natural estrogen (estetrol), which has marketing rights in Japan and Southeast Asia.
In the Association of Nations (ASEAN) region, Fuji acquired it from Estetra SRL.
Fuji Alyssa is preparing to launch the combination pill under the trade name to provide a new treatment option for dysmenorrhoea patients.
Related news
Young people value sustainability and environmental protection the most
According to the a joint survey by the Bosch Group…
Read more >
According to a survey, young people value sustainability and environmental expectations the most
Young people primarily expect sustainability and the protection of environmental…
Read more >Related news
Why are parcel locker providers getting stuck? This data points to the reasons
Parcel terminals are becoming increasingly popular: this year, nearly three-quarters…
Read more >
Using 30% less materials would be a solution to the climate crisis
The circular economy is a global imperative: it transcends geographical…
Read more >
Sustainability and health: the rise of plant-based dairy products in Hungary
In recent years, plant-based dairy alternatives have gained significant popularity…
Read more >
